Neuren Pharmaceuticals Shares Surge 36% on Positive European Opinion for Rett Syndrome Drug

SYDNEY — Shares in Neuren Pharmaceuticals Ltd skyrocketed more than 36% on Monday after the Australian biotech company's partner received a key positive recommendation for its Rett syndrome treatment in Europe, marking a significant regulatory milestone for the rare disease therapy.

Neuren's stock closed at 16.60 Australian dollars, up 4.40 dollars or 36.07%, on heavy trading volume following the announcement that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending marketing authorization for DAYBU (trofinetide).

The development positions DAYBU as a potential first treatment for neurobehavioral symptoms of Rett syndrome in the European Union, offering hope to patients and families affected by the rare genetic neurological disorder.

Under its partnership with U.S.-based Acadia Pharmaceuticals, Neuren stands to benefit from milestone payments and royalties if the drug gains final approval. The CHMP opinion follows a re-examination procedure after an earlier negative trend, highlighting the value of additional data and real-world evidence.

Acadia announced that the CHMP recommended granting marketing authorization for DAYBU for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. The European Commission is expected to issue a final decision in the coming months.

Rett syndrome is a complex, rare disorder primarily affecting girls, characterized by severe impairments in communication, motor skills and daily functioning. There has been limited treatment options available, making this potential approval a landmark moment for the community.

Neuren licensed trofinetide to Acadia for North American rights earlier, with the drug already approved and marketed as DAYBUE in the United States. Strong U.S. sales performance, including recent quarterly growth and new formulations like DAYBUE STIX, have provided substantial royalty income to Neuren.

The European opportunity expands the drug's potential reach significantly. If approved across the EU, it would cover 27 member states plus additional countries like Iceland, Liechtenstein and Norway, unlocking new revenue streams through tiered royalties.

Analysts and investors reacted positively to the news, viewing it as validation of trofinetide's clinical profile despite earlier regulatory hurdles in Europe. The re-examination process incorporated further evidence from clinical trials and post-approval use in the U.S., where more than 1,000 patients have been treated.

Neuren has been advancing its broader pipeline, including NNZ-2591 for other rare neurological conditions such as Phelan-McDermid syndrome, Pitt Hopkins syndrome and hypoxic-ischemic encephalopathy. Progress on these wholly-owned assets provides additional long-term growth drivers beyond DAYBUE royalties.

The company's financial position remains strong, supported by consistent royalty inflows from U.S. sales. In the first quarter of 2026, DAYBUE net sales reached approximately US$101 million, up 20% year-over-year, demonstrating robust demand.

Market watchers note that Neuren's market capitalization has now climbed substantially, reflecting renewed confidence in its ability to deliver value from its rare disease focus. The stock had faced some volatility earlier in the year amid regulatory uncertainty in Europe but rebounded sharply on today's news.

For the Rett syndrome community, the CHMP positive opinion brings renewed optimism. Advocacy groups have welcomed the step forward, emphasizing the urgent need for effective therapies that can improve quality of life for those living with the condition.

Industry experts point to the challenges of developing drugs for rare diseases, where small patient populations and complex endpoints often complicate regulatory reviews. The successful re-examination underscores the importance of persistence and comprehensive data packages.

Neuren's business model, centered on licensing key assets while retaining rights in certain regions and advancing its own pipeline, has proven effective. The partnership with Acadia has accelerated commercialization in major markets while providing Neuren with non-dilutive funding for further research.

Looking ahead, final European Commission approval would trigger additional milestone payments to Neuren. Longer term, successful launches in Europe could significantly boost royalty revenues, complementing U.S. growth and pipeline developments.

Investors will be closely monitoring the European Commission's decision timeline and any updates on Neuren's NNZ-2591 programs. Positive momentum in the U.S. market, including new formulation adoption, bodes well for international expansion.

The surge in Neuren's share price highlights the high-stakes nature of biotech investing, where regulatory catalysts can drive substantial value changes. With a focus on addressing unmet needs in neurodevelopmental disorders, the company continues to attract attention from both healthcare specialists and general market participants.

Broader market context shows strength in healthcare and biotech sectors amid ongoing interest in innovative therapies. Neuren's performance stood out on the Australian Securities Exchange, contributing to positive sentiment in the health care index.

As the company navigates this pivotal period, its commitment to rigorous science and patient-focused development remains central. Success in Europe would not only validate trofinetide further but also support continued investment in the next wave of potential treatments.

Patients, caregivers and clinicians eagerly await the final regulatory nod, which could transform treatment landscapes across the continent. In the meantime, Neuren's progress reinforces Australia's growing role in global biotech innovation.